

# The Renal Manifestations of Thyroid Disease

Laura H. Mariani and Jeffrey S. Berns

Renal, Electrolyte, and Hypertension Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

## ABSTRACT

Thyroid hormones influence renal development, kidney structure, renal hemodynamics, GFR, the function of many transport systems along the nephron, and sodium and water homeostasis. These effects of thyroid hormone are in part due to direct renal actions and in part are mediated by cardiovascular and systemic hemodynamic effects that influence kidney function. As a consequence, both hypothyroidism and hyperthyroidism associate with clinically important alterations in kidney function and have relevance to its assessment. Disorders of thyroid function have also been linked to development of immune-mediated glomerular injury, and alterations in thyroid hormones and thyroid hormone testing occur in patients with kidney disease.

*J Am Soc Nephrol* 23: 22–26, 2012. doi: 10.1681/ASN.2010070766

Thyroid hormone affects nearly every organ system in the body. It is produced and secreted by the thyroid gland under the control of the anterior pituitary hormone thyroid stimulating hormone (TSH), which is, in turn, regulated by hypothalamic thyrotropin-releasing hormone. Thyroxine (T<sub>4</sub>) is produced only by the thyroid gland, whereas triiodothyronine (T<sub>3</sub>), the more biologically active form of thyroid hormone, is produced primarily through local deiodination of T<sub>4</sub> by the enzyme T<sub>4</sub>-5'-deiodinase in other tissues, including the kidney. The kidney contains the D1 isoform of this enzyme, which becomes less active in uremia.<sup>1</sup> Thyroid hormone exerts its effect primarily through binding to thyroid hormone nuclear receptors, which then affect gene transcription by binding to thyroid hormone response elements of target genes. Thyroid hormones can also exert nongenomic effects by binding to elements on the plasma membrane and cytoplasm.<sup>2,3</sup>

## IMPACT OF THYROID HORMONE ON RENAL GROWTH AND DEVELOPMENT

In experimental animals, the availability of thyroid hormone affects kidney size, weight, and structure both during development and in adults. Histologic studies document the effects of thyroid hormone on cortical and outer medullary tubular segments, particularly involving the proximal tubule, distal convoluted tubule, and medullary thick ascending limb.<sup>4–6</sup> In neonatal rats, hypothyroidism decreases kidney size and weight, tubule length and diameter, and, to a lesser extent, glomerular volume.<sup>7–9</sup> These changes invariably reverse with thyroid hormone replacement. Hypothyroidism also blunts compensatory hypertrophy after unilateral nephrectomy in remnant kidney models.<sup>10,11</sup> Conversely, kidney to body weight ratios in hyperthyroid animals increase by as much as 30%.<sup>12,13</sup>

Children with congenital hypothyroidism have reduced renal mass and a higher prevalence of renal and urologic abnormalities, including dysplastic kidney, renal agenesis, ectopic kidney, hydronephrosis, posterior urethral valves, and hypospadias.<sup>14</sup> Mutations in the gene encoding *Pax8*, a transcription factor important for normal development and function, may, in some patients, be the link between congenital hypothyroidism and renal dysmorphogenesis.<sup>15</sup>

Although the exact mechanisms of the changes in kidney size are unknown, there is evidence that direct activation of the renin–angiotensin–aldosterone system by thyroid hormone can be independent of effects on hemodynamics.<sup>12</sup> Kobori *et al.*<sup>16</sup> have demonstrated that renal hypertrophy seen in hyperthyroid rats is blocked with losartan but not with nicardipine. This group has also demonstrated that the promoter activity of the renin gene in Calu-6 cells is stimulated by thyroid hormone through a thyroid hormone response element–dependent mechanism, increasing expression of mRNA encoding renin.<sup>16</sup> Whether some renin–angiotensin–aldosterone system

Published online ahead of print. Publication date available at [www.jasn.org](http://www.jasn.org).

**Correspondence:** Dr. Jeffrey S. Berns, University of Pennsylvania School of Medicine, Renal, Electrolyte and Hypertension Division, Presbyterian Medical Center, 39th and Market Streets, MOB #240, Philadelphia, PA 19104. Email: [bernsj@uphs.upenn.edu](mailto:bernsj@uphs.upenn.edu)

Copyright © 2012 by the American Society of Nephrology

component serves directly or indirectly as a thyroid hormone–modifiable growth factor is unclear.

Thyroid hormone is also important in the development of tubular function in both the prenatal and postnatal periods. In experimental animals, thyroid hormone affects the maturation, activity, and density of the  $\text{Na}^+$ -Pi cotransporter, increases  $\text{Na}^+$ - $\text{H}^+$  exchanger and  $\text{Na}^+$ - $\text{K}^+$ -ATPase activity, and plays a role in the isoform switch from neonatal  $\text{Na}^+$ - $\text{H}^+$  exchanger 8 to adult  $\text{Na}^+$ - $\text{H}^+$  exchanger 3.<sup>17–20</sup>

### DIRECT EFFECTS OF THYROID HORMONE ON RENAL TUBULAR FUNCTION

Thyroid hormone directly influences the expression and/or activity of a number of ion channels and transporters (Table 1). In some cases, this is due to direct binding of thyroid hormone to the promoter region of a transporter gene.<sup>21</sup> Examples of the effects of these changes can be seen clinically in both hyperthyroid and hypothyroid patients.

Hyperthyroidism is associated with polyuria, which is due to a combination of direct downregulation of aquaporin 1 and 2 along with increased BP, cardiac output, and renal blood flow. Food and water intake are also increased, as is catabolic rate. All of these factors may increase distal delivery of sodium, despite upregulation of the  $\text{Na}^+$ - $\text{K}^+$ - $2\text{Cl}^-$

cotransporter, other solutes, and water, resulting in increased urine flow rate.<sup>13</sup>

Hyponatremia due to impaired water excretion is a common complication of clinical hypothyroidism. Studies in hypothyroid animals demonstrate reduced capacity to achieve maximal urinary dilution due to nonosmotic arginine vasopressin release, as well as impaired urinary concentrating ability, increased urinary sodium excretion, increased fractional excretion of sodium, and impaired tolerance of sodium restriction.<sup>22</sup> These animals exhibit decreased  $\text{Na}^+$ - $\text{H}^+$  exchanger and  $\text{Na}^+$ -Pi cotransporter activity. Micro-puncture studies also show reduced sodium reabsorption in both proximal and distal tubule segments, abnormalities that are corrected with thyroid hormone replacement.<sup>22,23</sup> A small study in five hypothyroid men given an acid load demonstrated a decreased ability to acidify the urine.<sup>24</sup>

### HEMODYNAMIC CHANGES IN THYROID DISEASE

That thyroid disease exerts dramatic effects on the cardiovascular system has been known for many decades.<sup>25–27</sup> Thyroid hormone directly affects cardiac myocytes by regulating genes important for myocardial contraction and electrochemical signaling, including positively regulating sarcoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase,  $\alpha$ -myosin heavy chain,  $\beta$ 1-adrenergic receptors, guanine nucleotide regulatory proteins,  $\text{Na}^+$ - $\text{K}^+$ -ATPase, and voltage-gated potassium channels and negatively regulating  $\beta$ -myosin heavy chain, phospholamban,  $\text{Na}^+$ - $\text{Ca}^{2+}$  exchanger, and adenylyl cyclase types V and VI.

Thyroid hormone also affects vascular smooth muscle tone and reactivity. Most importantly, nitric oxide synthase activity increases in the kidney, heart, aorta, and cava in hyperthyroid rats. Hypothyroid rats showed a more mixed picture, with reduced activity in the aorta and cava but increased activity in the heart and stable activity in the kidney.<sup>28</sup> Hypothyroid animals also exhibit a decreased sensitivity to adrenergic vasoconstrictors and endothelium-dependent vasodilators.<sup>27,28</sup>

As a consequence of these cardiac and vascular effects, hyperthyroidism can increase cardiac output up to threefold by increased heart rate, increased inotropy, and decreased systemic vascular resistance.<sup>26</sup> Not surprisingly, renal blood flow also increases by direct measurement in hyperthyroid rats.<sup>13</sup> Opposite but equally dramatic hemodynamic effects occur in hypothyroid patients and experimental animals.<sup>26</sup> In adult animals, hypothyroidism (generally the result of thyroidectomy) reduces single nephron GFR, renal plasma flow, and glomerular transcapillary hydrostatic pressure.<sup>10,29</sup>

### GFR AND THYROID DYSFUNCTION

Many case reports and small case series document increased levels of serum creatinine with hypothyroidism in humans.<sup>30–34</sup> The importance of understanding the impact of thyroid dysfunction on renal function is highlighted by recent studies indicating subclinical and clinical hypothyroidism is common in patients with estimated GFR < 60 ml/min per 1.73 m<sup>2</sup>, begging the question of whether hypothyroidism might be contributing to the low GFR in some of these individuals.<sup>35,36</sup>

Serum creatinine levels in excess of 6 mg/dl have been attributed to hypothyroidism, with a few patients even described as having ESRD, although in most reports, creatinine levels have been in the range 1.5–2.5 mg/dl. Elevation of levels of serum creatinine can occur within as little as 2 weeks of significant hypothyroidism. These levels typically normalize rapidly with thyroid hormone replacement after short periods of hypothyroidism,<sup>33</sup> but slower and incomplete recovery has been noted with more prolonged periods of severe hypothyroidism. Similarly, multiple human and animal studies demonstrate a decreased serum creatinine in the setting of hyperthyroidism, which is similarly reversible upon treatment.<sup>34</sup>

Most of these case reports, however, rely on estimations of kidney function using creatinine-based estimating equations,

**Table 1.** Renal tubular ion transporters affected by thyroid hormone

$\text{Na}^+$ - $\text{K}^+$ ATPase
$\text{H}^+$ -ATPase
$\text{Na}^+$ - $\text{HCO}_3^-$ exchanger
$\text{Na}^+$ - $\text{H}^+$ exchanger
$\text{Na}^+$ -Pi IIa exchanger
$\text{Na}^+$ -sulfate exchanger
$\text{Na}^+$ - $\text{K}^+$ - $2\text{Cl}^-$ cotransporter
$\text{Na}^+$ - $\text{Ca}^{2+}$ exchanger
$\text{Cl}^-$ channel
AQP 1 and 2

Transporter function is decreased with hypothyroidism and increased with hyperthyroidism or thyroid hormone replacement with the exception of AQP, which has the opposite pattern.<sup>54–60</sup> AQP, aquaporin.

so the extent to which these changes reflect changes in true GFR as opposed to alterations in creatinine metabolism or tubular secretion or to an underlying myopathy has been unclear. Karanikas and colleagues<sup>37</sup> performed <sup>51</sup>Cr-EDTA isotopic renal scans in thyroidectomized patients with severe hypothyroidism (mean TSH  $70 \pm 23$   $\mu$ IU/ml) before and after thyroid hormone replacement. A fall in serum creatinine with thyroid hormone replacement ( $1.30 \pm 0.44$  versus  $1.04 \pm 0.32$  mg/dl) was associated with an increase in GFR by <sup>51</sup>Cr-EDTA clearance ( $61 \pm 18$  versus  $75 \pm 23$  ml/min). In another study of hypothyroid patients, estimated renal plasma flow, measured by <sup>131</sup>I-hippuran clearance, increased from  $542.8 \pm 215.8$  to  $717.0 \pm 140.6$  ml/min per  $1.73\text{m}^2$ , and GFR, measured with <sup>52</sup>Cr-EDTA clearance, increased from  $99.6 \pm 32.2$  to  $125.7 \pm 41.2$  ml/min after thyroid hormone replacement,<sup>38</sup> thus confirming that changes in levels of serum creatinine in patients with

thyroid disorders do reflect actual changes in GFR. These changes in GFR are likely due to a number of factors (Figure 1).


Cystatin C is a cysteine proteinase inhibitor that is produced at a constant rate by most nucleated cells, freely filtered at the glomerulus, and then reabsorbed and metabolized by proximal tubular epithelial cells.<sup>39</sup> Somewhat surprisingly, studies in humans and animals show that serum cystatin C levels generally trend in the opposite direction to those of creatinine<sup>40,41</sup>; that is, cystatin C is commonly elevated in hyperthyroid patients and decreased in hypothyroid patients. This pattern has been demonstrated in a wide range of causes and severity of thyroid diseases<sup>42</sup> and is hypothesized to be a direct effect of thyroid hormone on cystatin C production, although the exact mechanism is not known. Cystatin C should not be used for assessment of GFR in patients with thyroid disease.

## GLOMERULAR DISEASE IN PATIENTS WITH THYROID DISEASE

Isolated cases of reversible proteinuria and biopsy-proven GN associated with hypothyroidism and hyperthyroidism, most commonly in relationship to autoimmune thyroiditis, are reported in animals, as well as children and adults.<sup>30</sup> Where available, renal histopathology has revealed membranous nephropathy, minimal change, membranoproliferative GN, and IgA nephropathy. Whereas a direct pathogenic link between autoimmune thyroid disease and glomerular disease is uncertain, immune-mediated processes affecting both have been proposed, and there are reports of thyroid peroxidase and thyroglobulin deposits in the kidney.<sup>43</sup> Glomerular disease has also been described after therapy for hyperthyroidism: specifically, antineutrophil cytoplasmic antibody-positive crescentic GN after therapy with propylthiouracil<sup>44</sup> and membranous nephropathy after <sup>131</sup>I treatment.<sup>45</sup>

## THYROID FUNCTION TESTS IN PATIENTS WITH KIDNEY DISEASE

The kidney plays a role in clearance of iodine, TSH, and thyrotropin-releasing hormone. However, most patients with CKD are euthyroid, with normal TSH and free T4 levels. Patients with AKI and some with advanced CKD may have changes in thyroid function tests consistent with the euthyroid sick syndrome; that is, low T4, T3, and TSH concentrations.<sup>30,46,47</sup> Unlike most patients with euthyroid sick syndrome, those with renal failure typically have normal rather than increased reverse T3 levels.<sup>30,46</sup> ESRD patients have decreased levels of free T3.<sup>48</sup> These changes seen in patients with CKD and ESRD are due to alterations in the peripheral 5'-monodeiodination of T4, reduced levels of plasma proteins that bind T4, the presence of inhibitors of T4 binding to plasma proteins, metabolic acidosis, and effects of medications.<sup>48–50</sup> Heparin and furosemide, among other drugs, inhibit T4 binding to plasma



**Figure 1.** Multiple direct and indirect effects of thyroid hormone on GFR. NOS, nitric oxide synthase; SVR, systemic vascular resistance; CO, cardiac output.

proteins and may transiently elevate free T4 levels.<sup>51</sup> Thyroid gland enlargement, thyroid nodules, and thyroid carcinoma are also more common in patients with severe CKD than in the general population.<sup>52</sup>

Patients with nephrotic syndromes have urinary losses of proteins that bind thyroid hormones, including thyroxine binding globulin, transthyretin, and albumin.<sup>30</sup> This can result in reductions in total plasma T4 and less commonly total T3 levels that are roughly proportional to the severity of hypoalbuminemia and degree of proteinuria.<sup>30</sup> Many such patients remain euthyroid, however, as the result of increased secretion of TSH and thyroid hormone synthesis, although clinical hypothyroidism can occur.<sup>53</sup> Patients with nephrotic syndrome who are on exogenous thyroid hormone replacement may need an increase in their levothyroxine dose to maintain a euthyroid state.<sup>30</sup>

Thyroid hormones influence renal development, kidney structure, renal hemodynamics, GFR, the function of many transport systems along the nephron, and sodium and water homeostasis. Effects of hypothyroidism and hyperthyroidism on kidney function are the result of direct renal effects, as well as systemic hemodynamic, metabolic, and cardiovascular effects. Fortunately, most of the renal manifestations of thyroid disorders, which are clinically most significant with hypothyroidism, are reversible with treatment. Patients with hypothyroidism can have clinically important reductions in GFR, so screening for hypothyroidism should be considered in patients with unexplained elevations in serum creatinine. Serum cystatin C levels are not accurate indicators of GFR in such patients, however, and the accuracy of serum creatinine-based estimating equations in patients with hypothyroidism also is uncertain. Patients with thyroid disorders are also at risk for immune-mediated glomerular diseases. Finally, patients with nephrotic syndrome, as well as acute and chronic kidney injury, have alterations in thyroid gland physiology that can impact thyroid function and the testing of thyroid function status.

## DISCLOSURES

None.

## REFERENCES

- Lim VS, Passo C, Murata Y, Ferrari E, Nakamura H, Refetoff S: Reduced triiodothyronine content in liver but not pituitary of the uremic rat model: Demonstration of changes compatible with thyroid hormone deficiency in liver only. *Endocrinology* 114: 280–286, 1984
- Cheng SY, Leonard JL, Davis PJ: Molecular aspects of thyroid hormone actions. *Endocr Rev* 31: 139–170, 2010
- Brent GA: The molecular basis of thyroid hormone action. *N Engl J Med* 331: 847–853, 1994
- Davis RG, Madsen KM, Fregly MJ, Tisher CC: Kidney structure in hypothyroidism. *Am J Pathol* 113: 41–49, 1983
- Bentley AG, Madsen KM, Davis RG, Tisher CC: Response of the medullary thick ascending limb to hypothyroidism in the rat. *Am J Pathol* 120: 215–221, 1985
- Salomon MI, Di Scala V, Grishman E, Brenner J, Churg J: Renal lesions in hypothyroidism: A study based on kidney biopsies. *Metabolism* 16: 846–852, 1967
- Bradley SE, Coelho JB, Sealey JE, Edwards KD, Stéphan F: Changes in glomerulotubular dimensions, single nephron glomerular filtration rates and the renin-angiotensin system in hypothyroid rats. *Life Sci* 30: 633–639, 1982
- Canavan JP, Holt J, Easton J, Smith K, Goldspink DF: Thyroid-induced changes in the growth of the liver, kidney, and diaphragm of neonatal rats. *J Cell Physiol* 161: 49–54, 1994
- Slotkin TA, Seidler FJ, Kavlock RJ, Bartolome JV: Thyroid hormone differentially regulates cellular development in neonatal rat heart and kidney. *Teratology* 45: 303–312, 1992
- Falk SA, Buric V, Hammond WS, Conger JD: Serial glomerular and tubular dynamics in thyroidectomized rats with remnant kidneys. *Am J Kidney Dis* 17: 218–227, 1991
- Stéphan F, Réville P, de Laharpe F, Köll-Back MH: Impairment of renal compensatory hypertrophy by hypothyroidism in the rat. *Life Sci* 30: 623–631, 1982
- Kobori H, Ichihara A, Miyashita Y, Hayashi M, Saruta T: Mechanism of hyperthyroidism-induced renal hypertrophy in rats. *J Endocrinol* 159: 9–14, 1998
- Wang W, Li C, Summer SN, Falk S, Schrier RW: Polyuria of thyrotoxicosis: downregulation of aquaporin water channels and increased solute excretion. *Kidney Int* 72: 1088–1094, 2007
- Kumar J, Gordillo R, Kaskel FJ, Druschel CM, Woroniecki RP: Increased prevalence of renal and urinary tract anomalies in children with congenital hypothyroidism. *J Pediatr* 154: 263–266, 2009
- Park SM, Chatterjee VK: Genetics of congenital hypothyroidism. *J Med Genet* 42: 379–389, 2005
- Kobori H, Hayashi M, Saruta T: Thyroid hormone stimulates renin gene expression through the thyroid hormone response element. *Hypertension* 37: 99–104, 2001
- Baum M, Dwarakanath V, Alpern RJ, Moe OW: Effects of thyroid hormone on the neonatal renal cortical Na<sup>+</sup>/H<sup>+</sup> antiporter. *Kidney Int* 53: 1254–1258, 1998
- Euzet S, Lelièvre-Pégurier M, Merlet-Bénichou C: Maturation of rat renal phosphate transport: effect of triiodothyronine. *J Physiol* 488: 449–457, 1995
- Gattineni J, Sas D, Dagan A, Dwarakanath V, Baum M: Effect of thyroid hormone on the postnatal renal expression of NHE8. *Am J Physiol Renal Physiol* 294: F198–F204, 2008
- Nakhoul F, Thompson CB, McDonough AA: Developmental change in Na<sub>2</sub>K-ATPase  $\alpha$ 1 and  $\beta$ 1 expression in normal and hypothyroid rat renal cortex. *Am J Nephrol* 20: 225–231, 2000
- Li X, Misik AJ, Rieder CV, Solaro RJ, Lowen A, Fliegel L: Thyroid hormone receptor  $\alpha$ 1 regulates expression of the Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE1). *J Biol Chem* 277: 28656–28662, 2002
- Schmitt R, Klusmann E, Kahl T, Ellison DH, Bachmann S: Renal expression of sodium transporters and aquaporin-2 in hypothyroid rats. *Am J Physiol Renal Physiol* 284: F1097–F1104, 2003
- Michael UF, Barenberg RL, Chavez R, Vaamonde CA, Papper S: Renal handling of sodium and water in the hypothyroid rat. Clearance and micropuncture studies. *J Clin Invest* 51: 1405–1412, 1972
- Oster JR, Michael UF, Perez GO, Sonneborn RE, Vaamonde CA: Renal acidification in hypothyroid man. *Clin Nephrol* 6: 398–403, 1976
- Graettinger JS, Muenster JJ, Checchia CS, Grissom RL, Campbell JA: A correlation of clinical and hemodynamic studies in patients with hypothyroidism. *J Clin Invest* 37: 502–510, 1958
- Klein I, Danzi S: Thyroid disease and the heart. *Circulation* 116: 1725–1735, 2007
- Vargas F, Moreno JM, Rodríguez-Gómez I, Wangenstein R, Osuna A, Alvarez-Guerra M, García-Esteban J: Vascular and renal function in experimental thyroid disorders. *Eur J Endocrinol* 154: 197–212, 2006
- Quesada A, Sainz J, Wangenstein R, Rodríguez-Gómez I, Vargas F, Osuna A: Nitric oxide synthase activity in hyperthyroid and hypothyroid rats. *Eur J Endocrinol* 147: 117–122, 2002
- Bradley SE, Stéphan F, Coelho JB, Réville P: The thyroid and the kidney. *Kidney Int* 6: 346–365, 1974
- Iglesias P, Díez JJ: Thyroid dysfunction and kidney disease. *Eur J Endocrinol* 160: 503–515, 2009

31. Mooraki A, Broumand B, Neekdoost F, Amirmokri P, Bastani B: Reversible acute renal failure associated with hypothyroidism: Report of four cases with a brief review of literature. *Nephrology (Carlton)* 8: 57–60, 2003
32. Montenegro J, González O, Saracho R, Aguirre R, González O, Martínez I: Changes in renal function in primary hypothyroidism. *Am J Kidney Dis* 27: 195–198, 1996
33. Kreisman SH, Hennessey JV: Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. *Arch Intern Med* 159: 79–82, 1999
34. den Hollander JG, Wulkan RW, Mantel MJ, Berghout A: Correlation between severity of thyroid dysfunction and renal function. *Clin Endocrinol (Oxf)* 62: 423–427, 2005
35. Chonchol M, Lippi G, Salvagno G, Zoppini G, Muggeo M, Targher G: Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. *Clin J Am Soc Nephrol* 3: 1296–1300, 2008
36. Lo JC, Chertow GM, Go AS, Hsu CY: Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. *Kidney Int* 67: 1047–1052, 2005
37. Karanikas G, Schütz M, Szabo M, Becherer A, Wiesner K, Dudczak R, Kletter K: Isotopic renal function studies in severe hypothyroidism and after thyroid hormone replacement therapy. *Am J Nephrol* 24: 41–45, 2004
38. Villabona C, Sahun M, Roca M, Mora J, Gómez N, Gómez JM, Puchal R, Soler J: Blood volumes and renal function in overt and subclinical primary hypothyroidism. *Am J Med Sci* 318: 277–280, 1999
39. Manetti L, Pardini E, Genovesi M, Campomori A, Grasso L, Morselli LL, Lupi I, Pellegrini G, Bartalena L, Bogazzi F, Martino E: Thyroid function differently affects serum cystatin C and creatinine concentrations. *J Endocrinol Invest* 28: 346–349, 2005
40. Fricker M, Wiesli P, Brändle M, Schwegler B, Schmid C: Impact of thyroid dysfunction on serum cystatin C. *Kidney Int* 63: 1944–1947, 2003
41. Goede DL, Wiesli P, Brändle M, Bestmann L, Bernays RL, Zwimpfer C, Schmid C: Effects of thyroxine replacement on serum creatinine and cystatin C in patients with primary and central hypothyroidism. *Swiss Med Wkly* 139: 339–344, 2009
42. Wiesli P, Schwegler B, Spinas GA, Schmid C: Serum cystatin C is sensitive to small changes in thyroid function. *Clin Chim Acta* 338: 87–90, 2003
43. Shima Y, Nakanishi K, Togawa H, Obana M, Sako M, Miyawaki M, Nozu K, Iijima K, Yoshikawa N: Membranous nephropathy associated with thyroid-peroxidase antigen. *Pediatr Nephrol* 24: 605–608, 2009
44. Yu F, Chen M, Gao Y, Wang SX, Zou WZ, Zhao MH, Wang HY: Clinical and pathological features of renal involvement in propylthiouracil-associated ANCA-positive vasculitis. *Am J Kidney Dis* 49: 607–614, 2007
45. Becker BA, Fenves AZ, Breslau NA: Membranous glomerulonephritis associated with Graves' disease. *Am J Kidney Dis* 33: 369–373, 1999
46. Kaptein EM, Levitan D, Feinstein EI, Nicoloff JT, Massry SG: Alterations of thyroid hormone indices in acute renal failure and in acute critical illness with and without acute renal failure. *Am J Nephrol* 1: 138–143, 1981
47. Wartofsky L, Burman KD: Alterations in thyroid function in patients with systemic illness: The "euthyroid sick syndrome". *Endocr Rev* 3: 164–217, 1982
48. Kaptein EM, Quion-Verde H, Chooljian CJ, Tang WW, Friedman PE, Rodriguez HJ, Massry SG: The thyroid in end-stage renal disease. *Medicine (Baltimore)* 67: 187–197, 1988
49. Wiederkehr MR, Kalogiros J, Krapf R: Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. *Nephrol Dial Transplant* 19: 1190–1197, 2004
50. Spaulding SW, Gregerman RI: Free thyroxine in serum by equilibrium dialysis: effects of dilution, specific ions and inhibitors of binding. *J Clin Endocrinol Metab* 34: 974–982, 1972
51. Herschman JM, Jones CM, Bailey AL: Reciprocal changes in serum thyrotropin and free thyroxine produced by heparin. *J Clin Endocrinol Metab* 34: 574–579, 1972
52. Kaptein EM: Thyroid hormone metabolism and thyroid diseases in chronic renal failure. *Endocr Rev* 17: 45–63, 1996
53. Gilles R, den Heijer M, Ross AH, Sweep FC, Hermus AR, Wetzels JF: Thyroid function in patients with proteinuria. *Neth J Med* 66: 483–485, 2008
54. Alcalde AI, Sarasa M, Raldúa D, Aramayona J, Morales R, Biber J, Murer H, Levi M, Sorribas V: Role of thyroid hormone in regulation of renal phosphate transport in young and aged rats. *Endocrinology* 140: 1544–1551, 1999
55. Garg LC, Tisher CC: Effects of thyroid hormone on Na-K-adenosine triphosphatase activity along the rat nephron. *J Lab Clin Med* 106: 568–572, 1985
56. Santos Ornellas D, Grozovsky R, Goldenberg RC, Carvalho DP, Fong P, Guggino WB, Morales M: Thyroid hormone modulates CIC-2 chloride channel gene expression in rat renal proximal tubules. *J Endocrinol* 178: 503–511, 2003
57. Cano A, Baum M, Moe OW: Thyroid hormone stimulates the renal Na/H exchanger NHE3 by transcriptional activation. *Am J Physiol* 276: C102–C108, 1999
58. Kumar V, Prasad R: Molecular basis of renal handling of calcium in response to thyroid hormone status of rat. *Biochim Biophys Acta* 1586: 331–343, 2002
59. Sagawa K, Murer H, Morris ME: Effect of experimentally induced hypothyroidism on sulfate renal transport in rats. *Am J Physiol* 276: F164–F171, 1999
60. Cadnapaphornchai MA, Kim YW, Gurevich AK, Summer SN, Falk S, Thurman JM, Schrier RW: Urinary concentrating defect in hypothyroid rats: Role of sodium, potassium, 2-chloride co-transporter, and aquaporins. *J Am Soc Nephrol* 14: 566–574, 2003